|
Avandia News 09/06/2008- The Food and Drug Administration will begin posting every three months a list of drugs whose safety is under investigation because of complaints brought to the agency's attention by drug companies, physicians and patients. More>>> 09/03/2008- Avandia has been the subject of widespread speculation that has brought drug manufacturer GlaxoSmithKline under fire for product liability claims. The drug, used to treat Type 2 diabetes, has been linked to cardiovascular deaths and serious health conditions. More>>> 09/02/2008- According to researchers at Wake Forest University, a class of oral drugs (the thiazolidinediones), which includes Avandia (rosiglitazone) and Actos (pioglitazone) may make heart failure worse in people with type 2 diabetes. More>>> 08/30/2008- Marina Del Ray, CA: Marla's mother, Vivian, died of heart failure less than a month after starting on Avandia. While Vivian was diabetic, Marla had no indication that her mother could suddenly die of heart failure. But now she wonders if Avandia played a role in her mother's death. More>>> 08/30/2008- A class action lawsuit filed this week against the makers of Avandia and the Canadian government alleges that the popular diabetes drug increases the risk of heart failure, heart attack and death for older users. More>>> 08/30/2008- In the hardest-hitting assessment of diabetes meds this year, two Wake Forest University researchers say regulators should restrict use of the glitazone class of drugs--which includes the long-suffering Avandia. More>>> 08/23/2008- Reno, NV: Lisa's father was diabetic and like many diabetics, he had difficulty regulating his blood sugar. So his doctor put him on Avandia to help. He died within 18 months of starting on the drug. More>>> 08/21/2008- Thousands of Australians who are taking the diabetes drug Avandia (rosiglitazone) have been urged by the drug's manufacturer to see their doctors following safety issues concerning the medication. More>>> 08/20/2008- MORE than 30,000 Australians taking the controversial diabetes drugs Avandia and Avandamet are being told to have their treatment reviewed after the medications were linked with heart failure and death. More>>> 07/28/2008- Charlotte N.C.: Vanessa is just 37 years old and diabetic. She is also someone who has survived several months on Avandia, but like many others, suffered avandia-related shortness of breath, swelling, liver problems. Luckily, she lived to tell about it. More>>> 07/28/2008- Seniors who take the popular Type 2 diabetes drug Avandia have a 60 percent higher risk of heart failure than patients who take other diabetes medications, according to a new data analysis conducted by the Institute for Clinical Evaluative Science in Toronto and published in the Journal of the American Medical Association. More>>> 07/15/2008- Charles' wife had diabetes, and she had been taking Avandia as prescribed by her doctor. But it didn't do her any good. She died at the age of 39, after having experienced a series of heart problems and resulting surgeries. More>>> 07/10/2008- The FDA is considering the possibility that required cardiovascular studies should be added to the approval process for diabetes drugs. There does seem to be a correlation between cardiovascular risks and diabetes medications. More>>> 07/08/2008- Two North Carolina patients have sued GlaxoSmithKline, claiming that the drug maker's diabetes pill, Avandia, caused their heart attacks. More>>> 07/03/2008- Clinical trial designs for diabetes drugs are not good enough at detecting cardiovascular risk with GlaxoSmithKline’s (GSK) Avandia being Exhibit A, according to experts at a Tuesday meeting of CDER’s Endocrinologic and Metabolic Drugs Advisory Committee. More>>> 07/01/2008- Drugs designed to control type 2 diabetes should be subjected to more thorough safety reviews to ensure they don't raise the risk of heart problems, U.S. Food and Drug Administration advisers said Wednesday. More>>> 06/25/2008- Sam P. is happy to no longer be taking Avandia. He says he suffered severe side effects shortly after starting the medication, although he did not realize Avandia could have been causing his health problems. More>>> 06/13/2008- Otis is a coach and teacher at a high school in Texas. He was put on Avandia for his diabetes approximately five years ago. In the fall of 2006 he was hospitalized for a heart attack More>>> 06/11/2008- The VA Diabetes Trial analysis that showed no extra cardiovascular risk from rosiglitazone (Avandia) should not be taken as conclusive, cautioned independent investigators and statisticians. More>>> 06/11/2008- In his blog, Derek Lowe considers possible reasons for GlaxoSmithKline’s major cuts in its research staff. More>>> 06/06/2008- When the American Diabetes Association convenes here June 6th for their annual meeting, there is little doubt that amongst the topics up for discussion will be the fall of Avandia. More>>> 05/30/2008- March 1st, 2007 was a day Larry remembers well because he walked into hospital while having a heart attack--his second within 24 hours. He didn’t know he was having a heart attack, and it was the last thing he expected, because he had been taking Avandia for six years. More>>> 05/16/2008- After being on Avandia for two years, Gail suffered a heart attack. When she was admitted to hospital, immediately following her heart attack, the doctors did an angiogram and found that all the arteries were blocked. More>>> 04/24/2008- GlaxoSmithKline, the world's No 2 pharmaceuticals firm, announced disappointing first-quarter results yesterday, with profits down on the same period last year, as sales of Avandia continued to fall. More>>> 04/22/2008- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the percentage of primary care physicians (PCPs) and endocrinologists who consider the cardiovascular safety of GlaxoSmithKline's Avandia to be a major concern increased more than nine-fold following publication of a meta-analysis. More>>> 04/14/2008- GlaxoSmithKline confirmed it has received a warning letter from the US Food and Drug Administration (FDA) related to reporting requirements for approved medicines. The letter follows a routine FDA inspection of GSK's reporting processes conducted last year. More>>> 04/14/2008- The two licensed glitazone anti diabetics, pioglitazone (Actos, Takeda) and rosiglitazone (Avandia, GlaxoSmithKline), now account for more than 50% of expenditure on oral hypoglycaemic drugs in the UK’s National Health Service (NHS). More>>> 04/11/2008- Every large-cap pharma seems to have at least one marketed drug that produces endless streams of woe for them. In GlaxoSmithKline's (NYSE: GSK) case, the drug in question is its type 2 diabetes compound, Avandia. More>>> 04/09/2008- GlaxoSmithKline Plc failed to report all the required studies on its diabetes drug Avandia to the Food and Drug Administration, the agency said in a warning letter released on Tuesday. More>>> 04/09/2008- GlaxoSmithKline Plc, Europe's largest drugmaker, failed to properly disclose studies of Avandia, the diabetes pill linked to potentially deadly side effects, U.S. regulators said. More>>> 04/08/2008- GlaxoSmithKline Plc, Europe's largest drugmaker, failed to properly disclose studies of the diabetes pill Avandia after it was linked to potentially deadly side effects, U.S. regulators said. More>>> 04/08/2008- GlaxoSmithKline Plc failed to report some post-marketing data on its diabetes drug Avandia, the U.S. Food and Drug Administration said in a warning to the company released on Tuesday. More>>> 04/08/2008- S GlaxoSmithKline (NYSE:GSK) Plc., said it has received a warning letter from the Food and Drug Administration, which points to failures in periodic reports to the agency about its troubled Avandia diabetes product. More>>> 04/07/2008- SCOTTISH doctors have said there is "no defense" for the use of a widely prescribed diabetes drug after warnings that it should not be used in patients with heart problems, The Scotsman can reveal.The consultants, who work in the NHS Greater Glasgow and Clyde area, recommend no new patients are given Avandia – also known as rosiglitazone.More>>> 03/30/2008 Early in August 2006, Vivian's mother went to the hospital in Edmonton to have some cancer tests done. However, when she arrived the doctors noticed that the left side of her body was swollen. They took her vital signs and noticed her heart was racing. She was admitted to hospital that day, and on further testing the doctors discovered that her heart was enlarged as well. Over the next few days the doctors were unable to bring Vivian's mother's heart rate under control and she died.More>>> 03/29/2008 The diabetes landscape is a tad riskier for drugs in development that have a safety glitch or two, and the bottom line could mean higher costs. 03/16/2008 - Donald McEwen was driving on I-480 when he saw an ad on the back of a bus recruiting people for a study on diabetes. More>>> 03/04/2008 - The government's watchdog agency is investigating whether the Food and Drug Administration's drug-review process cleared two blockbuster medications without sufficient proof of their safety or effectiveness. More>>> 03/04/2008 - In the wake of the controversy over the diabetes drug Avandia, the U.S. Food and Drug Administration is considering tougher standards for how and when diabetes drugs will be tested for risks to the heart. 02/25/2008 - A flood of drug safety warnings from the Food and Drug Administration may have physicians and patients suffocating from information saturation. More>>> 02/19/2008 — A series of surprising findings about some of the most widely accepted assumptions in medicine has renewed debate about how aggressively doctors use drugs to prevent and treat some of the nation's leading health problems. More>>> 02/14/2008 - An Oklahoma man is suing drugmaker GlaxoSmithKline in federal court, claiming its popular diabetes pill gave him heart problems that required bypass surgery. More>>> 02/04/2008 - So much for confidential peer review. Last May, a controversial paper in the New England Journal of Medicine (NEJM) reported that a popular diabetes drug—rosiglitazone, sold under the brand name Avandia—substantially hikes a user's risk of heart attack. More>>> 01/31/2008 - Weeks before an influential article was published last year in the New England Journal of Medicine linking the diabetes drug Avandia to a risk of heart attacks, a physician helping peer-review the article broke the Journal's confidentiality rules and leaked a copy to the drug's maker, GlaxoSmithKline PLC. More>>> 01/31/2008 - A peer reviewer for the Waltham-based New England Journal of Medicine leaked a negative article about a diabetes drug to its manufacturer more that two weeks before the study appeared, another major scientific journal reports today. More>>> 01/30/2008 - A peer reviewer for The New England Journal of Medicine (NEJM ) broke confidentiality and leaked a damaging report about the blockbuster diabetes drug Avandia to the drug's manufacturer weeks ahead of publication, Nature has learned. More>>> 01/30/2008 - The wall between a prestigious medical journal and a major drug company may have been shattered. The scientific journal Nature reported today that a peer-reviewer for The New England Journal of Medicine leaked key study results on GlaxoSmithKline's diabetes drug Avandia to the company weeks before they were published. More>>> 01/25/2008 - Controversies about cholesterol drug Vytorin and diabetes drug Avandia are reigniting debate over what evidence the Food and Drug Administration requires to approve drugs -- and may generate pressure on the agency to raise its bar. More>>> 01/24/2008 - GlaxoSmithKline PLC said is to revise the labeling on its Avandia diabetes product to include additional warnings that the product may be associated with an increased risk of heart attacks, after a decision by the European regulator (CHMP) today. More>>>
01/21/2008 - Every year the Harvard Health Letter chooses what it considers to be the top 10 health stories of the year. During 2007, there weren't many instant breakthroughs that would qualify as scientific discoveries. Instead, we saw a slow, steady accumulation of data from multiple studies and clinical trials that finally reached a critical mass that could be considered an important health story. More>>> 01/17/2008 - I'm often asked, "How can I live to be 100 years old?" My answer is simple, "Just say no to prescription drugs and learn how to control insulin and blood sugar." More>>> 01/15/2008 - A professional doctors' group has petitioned the Food and Drug Administration to require that Avandia's warning label include a statement that a low-fat vegan diet is a safer, more effective approach to lowering blood sugar levels than the drug itself. More>>> 01/09/2008 - According to a November 2007 report by the Senate Finance Committee, an analysis by FDA scientists presented at a July 30, 2007, safety panel meeting estimates that Avandia has caused approximately 83,000 excess heart attacks since coming on the market. More>>> 01/08/2008 - Older patients who took Avandia had a higher risk of heart attacks, congestive heart failure and death than those on other diabetes pills, according to a study of nearly 160,000 Canadians. More>>> 01/03/2008 - An analyst with Merrill Lynch believes the controversy over cardiovascular risks posed by GlaxoSmithKline’s Avandia may have caused diabetics and their doctors to avoid treatment altogether. More>>> 12/24/2007 - Smokers taking the Pfizer drug Chantix to help them quit might have missed a Food and Drug Administration report in late November that the drug has been linked to drowsiness and suicidal thoughts. That's because while a drugmaker may issue a press release and the FDA an advisory when a drug is recalled or has a warning added, neither is obliged to directly notify consumers taking the drug, says Areta Kupchyk, a food and drug lawyer with the D.C. law firm Reed Smith. More>>> 12/23/2007 - Persistent questions about the safety of both prescription and over-the-counter drugs, a menacing microbe spreading throughout the U.S. and a globe-trotting TB patient garnered headlines this past year. More>>> 12/12/2007 - Older diabetes patients treated with Takeda Pharmaceutical North American Inc.'s Actos and GlaxoSmithKline PLC's Avandia had a "significant" increased risk of heart attack, congestive heart failure and death compared with those taking a more established treatment, according to a study in this week's Journal of the American Medical Association. More>>> 12/12/2007 - Older patients who took Avandia had a higher risk of heart attacks, congestive heart failure and death than those on other diabetes pills, according to a study of nearly 160,000 Canadians out Wednesday. More>>> 12/12/2007 - An independent analysis of thousands of older people with diabetes found that those treated with the widely used drug Avandia had significantly elevated risks of heart attack and death. 12/12/2007 - Canadian researchers furnished the strongest evidence to date linking the popular diabetes drug Avandia to an increased risk of heart attack in a scientific study released yesterday. More>>> 12/12/2007 - It must feel like Groundhog Day for GlaxoSmithKline as another analysis has been revealed which claims that Avandia, as well as Takeda’s Actos, is associated with an increased risk of congestive heart failure, heart attack and death compared with other oral diabetes drugs in older patients. More>>> 12/11/2007 - Older people taking GlaxoSmithKline Plc's Avandia and Takeda Pharmaceutical Co.'s Actos had a higher risk of heart attacks, failure and death than those taking other diabetes pills, a study by Canadian researchers showed. More>>> 12/11/2007 - Older patients treated with diabetes drug Avandia, sold by GlaxoSmithKline PLC, and Actos, made by Takeda Pharmaceutical Co. Ltd., have a significantly increased risk of heart attack, congestive heart failure and death compared to the other diabetes treatments More>>> 12/11/2007 - The popular diabetes medication Avandia is under scrutiny again. A new Canadian study finds that the drug, along with others like it, increases the risk of heart failure, heart attacks and death in older adults. More>>> 12/11/2007 - Another study has found evidence that certain diabetes drugs, especially GlaxoSmithKline's Avandia, can cause heart attacks and death, but the company said the findings did not make scientific sense. More>>>
12/08/2007 - Avandia places patients at a high risk of bone fractures and osteoporosis by affecting the way bone cells are replenished in the body. More>>> 12/07/2007 - GlaxoSmithKline’s controversial type 2 diabetes drug Avandia is back in the headlines following the news that two major pharmacy benefit managers in the USA are pulling the treatment from their formularies. More>>> 12/06/2007 - Slightly less than half of all patients who have discontinued the use of GlaxoSmithKline’s anti-diabetes drug Avandia over cardiac safety concerns were switched to Takeda Pharmaceuticals’ Actos, according to a healthcare information company. More>>> 12/06/2007 - HealthTrans Pharmacy and Therapeutics (P&T) Committee recommended removal of Avandia(R) (rosiglitazone) from its value-based formulary effective Jan. 1 due to concerns surfacing in clinical data in recent months. More>>> 12/5/2007 - Prescribing information about the diabetes drug rosi-glitazone (Avandia) is being updated to include a stronger warning about the risk of heart attack. More>>> 12/04/2007 - Drug developers are just beginning to grapple with recent FDA oversight reforms, but already industry and consumer advocates disagree on how well the overhaul will be able to prevent future drug safety scandals. More>>> 11/30/2007- The FDA should overhaul its approval process for new anti diabetics, argues Robert Misbin, from the FDA’s Division of Endocrinology and Metabolism and the medical officer who initially reviewed Avandia’s (rosiglitazone) application. More>>> 11/29/2007 - Doctors are taking a variety of approaches in response to Avandia's potential cardiac risks, with most opting either to switch diabetes patients to replacement drugs or to change dosage. More>>> 11/27/2007- Late yesterday, a bullet crossed the Dow Jones newswire saying, "FDA Warns GlaxoSmithKline on Breast-Cancer Drug Promotion." Almost immediately, my producer and I got a call from the CNBC staffer who was manning what we call our "Alerts Desk" asking us if we'd seen the news and if we could provide any context. We started digging, checking out the Glaxo and FDA web sites and placing calls to our GSK and FDA contacts. More>>> 11/27/2007- European and U.S. diabetologists called on Tuesday for greater caution in prescribing oral diabetes pills like GlaxoSmithKline Plc's Avandia, which has been linked to increased heart attack risk. More>>> 11/27/2007- A U.S. Food and Drug Administration official called for higher safety standards in approving diabetes drugs in the aftermath of fears about links between a top diabetes drug and heart attack risk. More>>> 11/27/2007- Two senior members of the Senate are seeking an interview with Tadataka Yamada, the former chairman of R&D for GlaxoSmithKline (GSK), to discuss his role in the alleged intimidation of John Buse, a professor at the University of North Carolina at Chapel Hill who raised concerns in 1999 about cardiovascular risks associated with Avandia. More>>> 11/26/2007- Six out of every 10 (61%) of the 408 respondents to a MedPage Today poll said the FDA should have been tougher when it ordered that a myocardial infarction warning be added to the black box warning for heart failure on the rosiglitazone (Avandia) label. More>>> 11/24/2007- When it comes to ensuring that prescription drugs are safe, the buck is supposed to stop with the U.S. Food and Drug Administration. More>>> 11/22/2007 - Avandia was approved in 1999. In recent years, some studies, including one last month, linked it to increased risk of heart attacks. The FDA voted this summer to beef up warnings on its label but keep it on the market. More>>> 11/20/2007- It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. More>>> 11/20/2007- Two high-ranking senators placed a report in the Congressional Record detailing how GlaxoSmithKline (GSK) employees allegedly intimidated a scientist who raised concerns over the company’s Type 2 diabetes drug Avandia. More>>> 11/19/2007- GlaxoSmithKline announced that it is implementing changes to the US product label for Avandia® (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti diabetic medicine available. More>>> 11/18/2007- The GlaxoSmithKline diabetes drug Avandia will have a new black box warning added to their product. The Black Box warning is the most severe warning a drug can have, and this is the second warning for Avandia. More>>> 11/17/2007- The Wall Street Journal reported Friday that Takeda Pharmaceutical Co. a company based in Japan planned to launch a massive ad campaign to remind patients that unlike Avandia its diabetes drug Actos does not increase risk of heart attack. More>>>
11/17/2007- Over a period of several years, drug maker GlaxoSmithKline PLC was so concerned about a prominent physician's negative views of its diabetes drug that it engaged in a concerted effort to intimidate him and stifle his opinion, a report by the U.S. Senate Finance Committee found. More>>> 11/16/2007- Here is the text of a statement issued by GlaxoSmithKline. More>>> 11/15/2007- GlaxoSmithKline PLC's Avandia, the world's best-selling diabetes drug last year, will carry US regulators' strongest warning on the risk of heart attacks. More>>> 11/15/2007- Avandia, the world's best-selling diabetes drug last year, will carry the Food and Drug Administration's strongest warning on the possible risk of heart attacks, the agency announced yesterday. More>>> 11/15/2007- After a fierce internal debate, federal drug officials have decided to allow Avandia, the controversial diabetes medicine, to remain on the market but insisted that a new warning about its heart risks be placed on its label. More>>> 11/14/2007- The FDA announced, in a press release November 14th, that the diabetes drug rosiglitazone (Avandia) will receive new information in the black box warning that is already in place on the drug's label. The updated information will include warnings that rosiglitazone may cause heart attacks. More>>> 11/14/2007- FDA informed healthcare professionals of new information added to the existing boxed warning in Avandia's prescribing information about potential increased risk for heart attacks. More>>> 11/14/2007- The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone),a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug’s labeling about potential increased risk for heart attacks. More>>> 11/14/2007- GlaxoSmithKline said Wednesday it is implementing changes to the U.S. product label for Avandia, based on a Food and Drug Administation review of myocardial ischemia data onthe diabetes drug. More>>> 11/14/2007- The Food and Drug Administration Wednesday toughened warnings on GlaxoSmithKline PLC's diabetes drug Avandia, saying the product was linked to a potential increase in the risk of heart attacks. More>>> 11/14/2007- The U.S. Food and Drug Administration issued the following safety alert on GlaxoSmithKline Plc'sdiabetes drug Avandia on Wednesday. More>>> 11/14/2007- GlaxoSmithKline Plc's diabetes pill Avandia will carry U.S. regulators' strongest warning on the risk of heart attacks. More>>> 11/14/2007- The U.S. Food and Drug Administration will announce its decision on GlaxoSmithKline Plc's diabetes drug Avandia within days, its deputy commissioner said on Tuesday. More>>> 11/06/2007- GlaxoSmithKline Inc., in consultation with Health Canada, has sent out a letter to health care professionals to inform them of important new restrictions on the treatment of type 2 diabetes mellitus with the rosiglitazone-containing products: Avandia(R) (rosiglitazone) More>>> 11/01/2007- They scuttle product launches and send company stocks through the floor. They steal precious years from patents and require pricey new trials. They have the entire drug industry on edge, from struggling one-hit biotech's to struggling large-cap pharma's.More>>> 10/31/2007- America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong." More>>> 10/30/2007- The U.S. Department of Veterans Affairs has deleted rosiglitazone (Avandia), the diabetes drug that has been linked to increased risk of myocardial infarction and heart failure, from its formulary. More>>>
10/29/2007- A senior Republican lawmaker asked the U.S. Food and Drug Administration to confirm that an internal FDA group privately voted to keep the troubled diabetes drug Avandia on the market by a one-vote margin, according to a letter made public on Monday. More>>> 10/29/2007- Last week, the Glaxo diabetes pill was in the news again because the FDA is now considering a second Black Box warning for heart attacks, in addition to an earlier warning for congestive heart failure. More>>> 10/24/2007- U.S. Food and Drug Administration officials are pushing for a "black box" warning of the risk of heart attack on GlaxoSmithKline Plc's diabetes drug Avandia More>>> 10/24/2007- The Food and Drug Administration wants GlaxoSmithKline PLC to add the strongest form of safety warning about heart-attack risk to the label of its diabetes drug Avandia 10/22/2007- The Department of Veterans Affairs (VA) has removed GlaxoSmithKline’s (GSK) Type 2 diabetes drug Avandia from its national formulary and is restricting the drug’s availability. 10/19/2007- GlaxoSmithKline is expected to unveil a £100 million slide in sales next week, led by flagging demand for Avandia, the diabetes drug which has been at the center of a safety scare over its heart risks. More>>> 10/18/2007- The U.S. Department of Veterans Affairs has decided to "severely limit" the use of GlaxoSmithKline Plc's diabetes drug Avandia over safety concerns, the New York Times reported on Wednesday. More>>> 10/18/2007- Dr. Steven Nissen is sticking to his guns. His latest target has been Avandia, the diabetes drug by GlaxoSmithKline: his analysis of 42 studies concluded it raises the risk of heart attack by 43 percent. More>>> 10/18/2007- GlaxoSmithKline PLC's Avandia diabetes medicine is to be relabeled with a stronger warning about heart attack risks after European authorities met to discuss all products in the diabetes class. More>>> 10/16/2007- An explosion of new research is vastly changing scientists’ understanding of diabetes and giving new clues about how to attack it. More>>> 10/5/2007- It is a statistic that is showing an alarming trend.The number of serious adverse drug events reported to the U.S. Food and Drug Administration has more than doubled between 1998 and 2005, as did deaths linked to such events, reports the Sept. 10 issue of Archives of Internal Medicine. More>>> 10/5/2007- The September 2007 Journal of the American Medical Association (JAMA) has published two new studies, one a meta-analysis of Avandia (rosiglitazone) and the other a meta-analysis of Actos (pioglitazone). More>>> 10/1/2007- A further pall has been cast over Avandia, a drug for Type 2 diabetes. A new study has found that long-term use of the pharmaceutical increases heart attack risk by more than 40 percent and doubles the chance of heart failure. More>>> 09/27/2007- The diabetes drugs Actos and Avandia raise the risk of heart failure but do not increase the risk of heart-related death, U.S. researchers said on Thursday, confirming earlier findings. More>>> 09/20/2007- People with diabetes face hazards aplenty, among them twice the normal risk of heart disease and stroke and up to four times the chance of a fatal heart-related event. More>>> 9/17/2007- A consumer watchdog group stands by its belief that Avandia, the embattled type 2 diabetes drug, should be removed from the market, a demand the group's leadership says was fortified last week by additional research.More>>> 9/12/2007- Avandia, GlaxoSmithKline's (GSK) controversial diabetes drug, has again come under fire after more research was released claiming that the treatment increases the risk of heart attacks. More>>> 9/12/2007- The diabetes drug Actos cuts the risk of heart attack, stroke and death, but raises the risk of heart failure, according to one study published on Tuesday, while a second confirmed disputed findings that rival Avandia raises heart risks. More>>> 9/12/2007- Two studies and an editorial today should lead the Food and Drug Administration to pull the diabetes pill Avandia off the market, the authors say. More>>> 9/12/2007- Scientists have discovered long-term use of the popular diabetes drug Avandia can increase a person's risk of heart attack. More>>> 9/10/2007 - The FDA recently announced that it will require manufacturers of certain diabetes drugs to add a stronger warning to their labeling about the risk of heart failure. More>>> 9/10/2007- A prominent New England researcher has rekindled a debate about the standards the Food and Drug Administration uses to speed approval of life-saving drugs, arguing that federal officials should insist on more rigorous proof that the drugs save lives and improve patients' health. More>>> 9/6/2007- Experiments in mice suggest that the type 2 diabetes drugs rosiglitazone (Avandia) and pioglitazone (Actos) increase uptake of both glucose and triglycerides in cardiac tissue, causing or exacerbating heart failure. 8/27/2007- Testimony of Sidney Wolfe M.D., Elizabeth Barbehenn Ph.D. and Ben Wolpaw, Health Research Group of Public Citizen. I will focus on the fourth question to the committee: Does the overall risk-benefit profile of rosiglitazone (Avandia) support its continued marketing in the US? More>>> 8/25/2007 - The maker of Avandia warns that this drug can cause fluid retention and congestive heart failure. Patients are cautioned that swelling, rapid weight gain, breathing problems or unusual tiredness may be serious and deserve immediate medical attention. More>>> 8/23/2007 - Avandia attitudes: Only nine percent of respondents said they would continue prescribing it without reservations, and one in four said it should be taken off the market. More>>> 8/15/2007- US regulators have approved new “black box” warning labels for GlaxoSmithKline's controversial diabetes drug Avandia. More>>> 8/15/2007- It might not be a skull and cross bones, but a "black box" warning is not the type of label that most pharmaceutical companies like to see on any of their products. More>>> 8/15/2007- The Food and Drug Administration said Tuesday that GlaxoSmithKline has agreed to use a so-called "black box" warning regarding the risk of heart failure for its Avandia type 2 diabetes drug. More>>> 8/15/2007- The diabetes drugs Avandia and Actos will be labeled with severe warnings about a risk of heart failure to some patients, health officials said Tuesday. More>>> 08/14/2007 - After a review of post marketing adverse event reports, FDA determined that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione class of antidiabetic drugs. This class includes Avandia. More>>> 8/13/2007- GlaxoSmithKline is considering cutting its pharmaceutical sales force in response to the collapse in sales of its diabetes drug Avandia. More>>> 08/13/2007- The controversial diabetes drug Avandia has been a problem for its maker, GlaxoSmithKline. Research has concluded the drug carries the risk of heart attack. More>>> 08/12/2007- A pair of votes July 30 by a Food and Drug Administration advisory panel offered mixed recommendations for the agency and signaled caution for physicians who prescribe Avandia. More>>> 08/10/2007- The Saudi Ministry of Health is to discuss the results of studies on Avandia, an anti-diabetes medicine also known as rosiglitazone, next week to see whether the medicine is safe for use. More>>> 08/08/2007- The debate over the heart-attack risks posed by the type 2 diabetes drug Avandia has taken another twist, with a new study questioning the results of the research that kick-started the controversy. More>>> 08/08/2007- While Avandia may still be viable for some patients in spite of increased risks for heart attack, stroke and kidney failure, most doctors are advocating a switch away from Avandia 08/06/2007 - Amid the allegations of increased heart attack risk with Avandia, a popular anti-diabetes drug, the general cost of prescription drugs and the horror stories of fake medicines from overseas, you may think about missing a dose. More>>> 08/06/2007- GlaxoSmithKline today welcomed the nearly unanimous recommendation of an U.S. Food and Drug Administration’s (FDA) advisory committee to support Avandia’s continued availability to patients in the US. More>>> 08/04/2007- They're just dropping like Chinese imports--prescription drugs that turn out to be deadly after FDA approval. More>>> 08/02/2007- "I logically can't find any way to leave this drug on the market," states Arthur Levin, director of the Center for Medical Consumers in New York. The drug Levin refers to is Avandia. More>>> 08/02/2007- An FDA advisory committee has recommended that GlaxoSmithKline's diabetes treatment Avandia should remain available on the US market, albeit with stronger health warnings. More>>> 08/01/2007- GlaxoSmithKline’s Avandia (rosiglitazone) appears likely to get stricter labeling, per the recommendation of an FDA advisory panel. More>>> 08/01/2007- It might offer some advantages for you, but some doctors said there are other medications that will treat diabetes without the possible side affects of Avandia, and they recommend patients consider switching and going off Avandia right away. More>>> 07/31/2007- Popular Drug Associated With Risks to Multiple Organ Systems Has No Benefit Over Older, Safer Type 2 Diabetes Drugs. More>>> 07/31/2007 - Most Colorado diabetics who were using Avandia, a drug that controls blood-sugar levels, were taken off it two months ago when a scientific article pointed to increased risks of heart problems. More>>> 07/30/2007 - One million Americans with Type-2 Diabetes take Avandia to control blood sugar; however studies show it can increase the risk of heart attacks by 43 percent. More>>> 07/30/2007- The U.S. government is looking into safety concerns about the diabetes treatment drug Avandia, with a top safety scientist urging that it be pulled from the market. More>>> 7/30/2007 - The widely used diabetes drug Avandia (rosiglitazone) provides no unique short term benefits to type 2 diabetics and should be withdrawn from the U.S. market because of heart risks, a FDA scientist said on July 30th. More>>> 7/30/2007 - One of the US FDA's scientists has called for GlaxoSmithKline's diabetes drug Avandia to pulled off the market because of the risk of heart disease. More>>> 7/27/2007 - The widely used diabetes drug Avandia increases the chance of serious heart problems, including a 30% to 40% higher risk of myocardial ischemia. More>>> 7/27/2007 - According to documents released on the FDA's website Thursday, FDA officials are concerned that users of Avandia may face an increased risk of heart attack. More>>> 7/27/2007 - The Times claimed that diabetics “face an increased risk of heart attacks while those who take Actos, a similar drug, do not..." More>>> 7/27/2007 - Neil Pender's father passed away five years ago from a heart attack and he is angry. "My father started taking Avandia shortly after it was approved in 1999 but we didn't hear about the dangers of this drug until June of this year" More>>> 7/27/2007 - Two of the most commonly used drugs for diabetes, which were taken by hundreds of thousands of mostly overweight people in the UK last year, are causing widespread heart failure. More>>> 7/27/2007 - Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, is one of the most distinguished physicians in the world. He has developed fame and notoriety due to his challenging of the safety of certain drugs. More>>> 7/27/2007 - A class of drugs commonly used to treat type 2 diabetes may double the risk of heart failure, according to a new analysis by researchers at Wake Forest University School of Medicine and colleagues. More>>> 7/27/2007 - A class of drugs commonly used to treat diabetes doubles the risk of heart failure, according to a new study. More>>> 7/25/2007 - On Monday, July 30, a panel of academic scientists will meet to advise the U.S. Food and Drug Administration as to what, exactly, the regulator should do about Avandia, the best-selling diabetes drug in the world. More>>> 7/24/2007 - GlaxoSmithKline is expected by analysts to report a fall in revenue of more than £100 million after a collapse in sales of Avandia, its diabetes medicine, which has been linked to an increased risk of heart attacks and strokes. More>>> 7/22/2007 - Back in the ’60s, when University of Michigan students were holding protests over civil rights and the Vietnam War, an undergraduate named Steven E. Nissen was at the center of the political dissent. More>>> 7/20/2007 - Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes. More>>> 7/19/2007 - GlaxoSmithKline Plc's Avandia, tainted by reports linking the drug to increased heart attack risks More>>> 7/18/2007 - A review of research reveals there is not much evidence to support using rosiglitazone (Avandia), a medication previously prescribed to lower blood glucose levels in adults with type two diabetes. More>>> 7/17/2007 - Though the FDA has yet to advise on the cardiovascular safety of GlaxoSmithKline's Avandia type 2 diabetes drug... Internists said they will switch more than half their type 2 diabetes patients currently on Avandia to another therapy. More>>> 7/17/2007 - Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes, according to a systematic review of data by German researchers More>>> 7/16/2007 - Most type 2 diabetes drugs are equally effective for lowering blood sugar, but the generic drug metformin has fewer side effects than several newer, pricier medications More>>> 07/16/2007 - An executive of the company that makes the diabetes drug Avandia said a researcher who was among the first to link it to heart problems. More >>> 05/22/2007 - A widely prescribed drug to treat Type 2 diabetes substantially increases the risk of heart attacks and death from cardiovascular disease, according to a study released today. 02/22/2007 - Women taking the diabetes drugs Avandia, Avandamet, or Avandaryl may be more likely to fracture their bones than those using other diabetes drugs. More >>> 11/15/2006 - A Food and Drug Administration panel is set to meet Thursday to discuss the safety review of 16 drugs. More >>> If you or a loved one have experienced an Avandia heart attack, or Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia lawyers of Ennis & Ennis, P.A. today about an Avandia lawsuit. Call us toll free for a free, confidential case evaluation or fill out our online Avandia case evaluation form. |
About Us NewsLinksContact Us